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Objective: To investigate the effect of magnetic nanoparticles (MNPs) of Fe3O4 combined with 
cyclosporin A (CsA) on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic 
stem cell transplantation (allo-HSCT) in murine models.
Methods: BALB/c mice preconditioned with total-body irradiation generated aGVHD and 
then were followed with allo-HSCT from allogeneic C57BL/6. Recipient mice were randomly 
divided into five groups and then given different supportive care and followed up. The physical 
signs and median survival time (MST) were recorded, peripheral blood cell counts were assessed, 
and histological changes of the main tissues were evaluated with hematoxylin-eosin staining. 
Furthermore, fluorescence polarization immunoassay was used to monitor the concentration 
of CsA.
Results: The irradiated-only mice developed typical aGVHD, and the typical signs of aGVHD 
in the skin, liver, and intestine were observed by histopathological examination. Both CsA 
alone and in combination with Fe3O4 MNPs significantly prolonged the MST of recipient mice 
compared with both the control and the Fe3O4 MNPs groups. Notably, a combination of CsA 
with Fe3O4 MNPs can elevate the peripheral white blood cells and alleviate the symptoms of 
GVHD and the pathological damage after allo-HSCT. In addition, the concentration of CsA 
was higher in plasma, heart, liver, and spleen of recipient mice with supporting care of the 
combination of CsA with Fe3O4 MNPs than with CsA alone.
Conclusion: Taken together, Fe3O4MNPs may be used as a carrier of immunosuppressive agents 
to alleviate GVHD after allo-HSCT in murine models.
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Introduction
Hematopoietic stem cell transplantation (HSCT) was originally one of the most effective 
treatments for various malignant and nonmalignant hematological diseases.1 With 
the development of research skills, HSCT has become one of the important means 
in the treatment of benign blood diseases, solid tumors, autoimmune disease, genetic 
disease, heart disease, neurological diseases, and other diseases. When attention was 
paid to this problem, graft-versus-host disease (GVHD) in allogenetic bone marrow 
transplantation (allo-HSCT) became a major complication; the incidence rate was as 
high as 40%–60%, and the mortality rate was almost 50%. The current main measures 
to prevent and treat GVHD are the application of cytotoxic drugs, immunosuppressive 
agents, or renovating of T cells in graft before and after transplantation. Cytotoxic 
drugs and immunosuppressive agents can decrease the recipient immune function and 
induce secondary infection and the occurrence of other tumors. The removal of  T cells International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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in grafts not only reduces the incidence of GVHD, but also 
weakens graft-versus-leukemia effect or graft-versus-tumor 
effect, which leads to leukemia or cancer recurrence and 
graft failure.2
Cyclosporine A (CsA), which has a moderate effect on 
GVHD, has become the basis for many of the immunosup-
pressive regimens; it has been especially successful when 
used for the treatment of GVHD following allogenetic 
bone marrow transplantation, but it has been associated 
with drawbacks, such as hepatotoxicity, neurotoxicity, and 
nephrotoxicity,3 so it is necessary to administer frequent doses 
of CsA to patients to prolong medium survival time (MST). 
Research has been proposed for stearic acid nanoparticles 
or solid lipid nanoparticles as a carrier to increase the oral 
absorption and relative bioavailability of cyclosporine.4,5 
Notably, the solid lipid nanoparticle in situ gel for bioadhesive 
CsA can reduce its dosage and side effects.6 The unique abil-
ity of magnetic nanoparticles (MNPs) to be functionalized 
with bioactive agents and respond to magnetic fields has made 
them useful for their stable performance, hardness, strong 
magnetism, simple preparation, and good biocompatibility. 
Despite MNPs having numerous advanced applications, the 
potential effects of pure MNPs on mammals’ transplantation 
have rarely been reported. The present study aimed to 
investigate the immunosuppressive role of CsA loaded with 
Fe3O4 MNPs in murine models after allo-HSCT.
Materials and methods
Animals
Pure inbred female BABL/c(H-2d) and male C57BL/6(H-2b, 
B6) mice (aged 10–12 weeks), weighing 18.5 ± 1.5 g were 
purchased from Shanghai National Center for Laboratory 
Animals. Mice were kept with a 12-hour light/dark cycle 
and given sterile water of erythromycin (250 mg/L) and 
gentamicin (320 mg/L) from 1 week prior to 2 weeks after 
bone marrow graft transplant to reduce intestinal microflora. 
All animal experiments were carried out in adherence with 
the Guidelines for the Care and Use of Laboratory Animals 
of the National Institute of Health.
Main reagents
Roswell Park Memorial Institute (RPMI) 1640 medium 
was supplied by GIBCO BRL, (Gaithersburg, MD). 
Cyclosporin A was supplied by North China Pharmaceuticals, 
Shijiazhuang, China. Fetal bovine serum (FBS) was supplied 
by Gibco Chemical Co (Carlsbad, CA). Anti-CsA mAb was 
supplied by Abbott Laboratories (North Chicago, IL).
Preparation of CsA-loaded Fe3O4 MNPs
Fe3O4 MNPs were produced by the electrochemical deposition 
under oxidizing conditions in a 0.1 M tetraheptylammonium 
2-propanol solution as described previously.7,8 The deposited 
clusters were capped with tetraheptylammonium, which acts 
as a stabilizer of the colloidal nanocrystallites.9 Before being 
applied in this experiment, the prepared Fe3O4 MNPs were 
well distributed in RPMI 1640 medium containing 10% (v/v) 
heat-inactivated FBS by using ultrasound treatment in order 
to obtain the Fe3O4 MNPs colloidal suspension. CsA was 
conjugated with Fe3O4 MNPs at the weight ratio of 1:400 by 
mechanical absorption polymerization at 4°C for 12 hours, 
as previously reported.8
Transplantation
To prepare for allo-HSCT, bone marrow cells were harvested 
from femurs, tibias, and spleen of donor C57BL/6 mice 
according to the methods described by Dobson and 
colleagues.10 Briefly, the epiphysis ends of femur and tibia 
were removed, the bone marrow cells in the bone marrow 
cavity were quickly removed, and the spleen was cut into 
small pieces, ground with a syringe needle core, and then 
flushed with RPMI 1640 medium containing 5% FBS to 
prepare for single cell suspension using a 200 mesh wire 
mesh filter. The erythrocyte was lysed, and the nucleated 
cells were washed with serum free RPMI 1640 medium 
twice. The cells were adjusted to 1 × 108/mL, and cell activity 
was assessed by trypan blue staining. Thereafter, 0.2 mL 
mixed bone marrow (1 × 108/mL) per mouse was prepared 
for transplantation.
Recipient BABL/c (H-2d) mice were subjected to total 
body irradiation (TBI) using a megavoltage linear accelerator 
with 60Coγ-rays (total dose: 8Gy) on day 0 to establish bone 
marrow graft transplant models in the radiotherapy centers 
of the Cancer Hospital of Jiangsu Province. The mice then 
received 0.2 mL donor mixed bone marrow cells via tail vein 
on the day of irradiation.
Following transplant, recipient mice were housed in micro-
isolator cages containing autoclaved bedding. Supportive care 
was identical for the recipient mice, and different prevention 
programs were used for acute GVHD (aGVHD) prophylaxis 
in three groups. Mice in the first group were given an 
intraperitoneal injection of CsA (1.5 mg ⋅ kg−1 ⋅ d−1) on the 
first day until bowel function was normal, and then the dose 
of CsA was changed to 5 mg ⋅ kg−1 ⋅ d−1; mice in the second 
group were given CsA (1.5 mg ⋅ kg−1 ⋅ d−1) combined with 
Fe3O4 MNPs (600 mg ⋅ kg−1 ⋅ d−1); and mice in the third group 
were given only Fe3O4 MNPs (600 mg ⋅ kg−1 ⋅ d−1). Meanwhile, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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irradiated mice without controlling GVHD after allo-HSCT 
and irradiated-only mice were regarded as control groups. 
Each supportively cared group was randomly divided into 
five subgroups (three mice each) for study on days 5, 10, 
15, 20, and 25.
evaluation of engraftment
The diagnosis and grading of aGVHD were established 
according to the previous definable criteria.11 Engraftment 
was evaluated by checking the animals daily for MST, 
peripheral blood cell counts, and signs of GVHD including 
hunched posture, wasting, skin lesions, and diarrhea.
At each time point, blood was collected from the retro-
orbital sinus into an EDTA (ethylenediaminetetraacetic acid) 
tube, and then diluted 1:10 in phosphate buffered saline. 
The number of white blood cells (WBCs) was assessed 
with   Sysmex XE-2100 hematology analyzer using standard 
protocols; once the absolute neutrophil count was more than 
0.5 × 109/L, the neutrophils were considered engrafted.
hematoxylin and eosin staining
The recipient mice were killed, and specimens of liver, 
small intestine, and ear skin were taken immediately. All 
tissues were initially fixed with 10% formalin, dehydrated 
in a graded alcohol series, and then embedded in paraffin. 
Slices (0.5 mm thick) were cut and stained with hematoxylin 
and eosin for microscopic examination. All sections were 
observed in a blinded manner and photomicrographed under 
a confocal microscope. The tissues from the irradiated but 
nontransplanted mice were treated in a similar fashion as 
control.
FPIA procedure
The level of CsA in plasma and tissues was measured 
using a fluorescence polarization immunoassay (FPIA) 
as previously described.12 In brief, 700 µL solubilization 
reagent and 100 µL precipitation reagent were added to each 
sample, vortex-mixed and allowed to stand for 5 minutes; the 
supernatant was transferred into their respective reaction cells 
and then measured using a fluorescence spectrophotometer 
at the excitation and emission wavelengths of 492/514 nm. 
The compounds were quantified using the ratio of their 
peak height to the internal standard, based on the calibration 
curve of CsA.
statistical analysis
All experiments were repeated at least three times, data were 
expressed as mean ± standard deviation and analyzed using 
SPSS (v 11.5; SPSS Inc, Chicago, IL). Survival analysis 
was performed using the Kaplan–Meier method. Differences 
among various groups were evaluated using one-way analysis 
of variance. A P-value of 0.05 was considered statistically 
significant.
Results
MsT after transplantation
The prevention of aGVHD with either CsA alone or in 
combination with Fe3O4 MNPs prolonged the survival of 
recipient mice compared with other groups (P , 0.05) 
(Figure 1), but there was no significant difference between 
CsA alone (22.3 ± 5.6 days) and the combination of CsA 
with Fe3O4 MNPs (23.6 ± 4.9 days) (P . 0.05). During the 
25 days’ observation, the MST of the irradiation-only mice 
(8.0 ± 1.6 days) was shorter than that of both the Fe3O4 
MNPs-treated group and the control group (P , 0.05), 
but there was no significant difference between the Fe3O4 
MNPs-treated group (16.1 ± 3.0 days) and the control group 
(16.8 ± 2.8 days) (P . 0.05).
Physiologic observation after 
transplantation
The weight of mice decreased in the first week. The survival 
recipients, except the irradiated-only mice, began to gain 
weight again from day 5, and then fell quickly from day 10, 
but there were no obvious weight changes in the Fe3O4 
MNPs-treated and control groups (P . 0.05). It is noteworthy 
that from day 10, the body weight decrease was less in the 
group of immunosuppressive CsA than in both the Fe3O4 
MNPs-treated and control groups, but there was no obvious 
difference between the CsA-only group and the CsA + Fe3O4 
MNPs-treated group. Notably, mice in the irradiated-only 
group developed clinical symptoms of aGVHD, including 
hair loss, diarrhea, and anal irritation; thereafter, all died 
before day 10. The mice without supporting care of CsA 
also developed aGVHD, and the symptoms of aGVHD were 
not relieved. The symptoms of aGVHD in the mice with 
supporting care of CsA progressively disappeared, and no 
obvious changes were observed during the follow-up after 
the supporting care of CsA (Figure 2).
Peripheral blood cell counts
WBC count in peripheral blood of the mice was from 
8.0 × 109/L to 9.0 × 109/L before allo-HSCT and decreased 
from 0.5 × 109/L to 5.0 × 109/L after allo-HSCT, suggesting 
that WBC count of mice is lower after allo-HSCT than that 
prior to transplantation. After transplantation for 5 days, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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WBC count in all recipient mice was less than 0.5 × 109/L. 
With the hematopoietic recovery, WBC increased gradually 
and reached from 4.0 × 109/L to 5.0 × 109/L in recipient mice 
with the supporting care of CsA alone or in combination with 
Fe3O4 MNPs and reached from 3.0 × 109/L to 4.0 × 109/L 
in the mice without supporting care of CsA (Figure 3). 
Unluckily, the WBC count of the irradiated-only mice was 
low and they all died of aplastic crisis or infection after 
irradiation for less than 1 week.
Concentration of cyclosporine
Concentration of cyclosporine in blood, heart, liver, and 
spleen in CsA-treated mice was all lower than that of mice 
treated with the combination of CsA and Fe3O4 MNPs, and 
there were statistically significant differences (P , 0.05); 
on the other hand, there was no significant difference in the 
tissues of lung, kidney, and brain between the two groups 
(P . 0.05), suggesting partly that Fe3O4 MNPs can increase 
the concentration of cyclosporine in blood and tissue of heart, 
liver, and spleen (Table 1).
histopathology
A reduced number of hair follicles and little sebaceous glands 
appended to the hair follicles was observed, and a diffuse 
and moderate lymphocytic infiltration was found around hair 
follicles and extending to the lower surface epidermis in the 
irradiated-only mice (Figure 4B). Inflammatory cells were 
also observed, but the hair follicles and sebaceous glands 
were not influenced in the mice treated with Fe3O4 MNPs 
alone after allo-HSCT (Figure 4C). No noticeable structural 
change was observed in the skin of mice with supported care 
of CsA, but the number of follicles was less in the CsA-only 
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treated mice than in the combination of CsA with Fe3O4 
MNPs (Figure 4D and E).
In liver, a severe, mixed inflammatory response and 
various degrees of focal degeneration and necrosis were 
noted near the central veins, and the liver tissue structure 
was unclear in the irradiation-only mice when compared 
with that of CsA-only or its combination with Fe3O4 MNPs 
(Figure 5B). On the other hand, local minor inflammatory 
response was also observed in liver tissue of mice in the Fe3O4 
MNPs-treated (Figure 5C) and control group (Figure 5A). It 
is noteworthy that the focal degeneration and necrosis were 
inconspicuous in both CsA and its combination with Fe3O4 
MNPs, and fewer inflammatory cells were presented when 
CsA was loaded with Fe3O4 MNPs (Figure 5D and E).
In histological sections of the intestinal tissues, those of 
coadministration of CsA with Fe3O4 MNPs were   significantly 
thick in submucosal-serosa compared with other groups. 
Numbers of inflammatory cells per image in fibrous 
thickening areas of either CsA or its combination with Fe3O4 
MNPs were less than that of both irradiation-only and Fe3O4 
MNPs-only group, but very few inflammatory cells appeared 
when CsA was loaded with Fe3O4 MNPs (Figure 6). No 
  obviously changes were observed, suggesting that Fe3O4 
MNPs are able to enhance the effect of CsA on alleviating 
intestinal damage after allo-HSCT.
Discussion
Allo-HSCT is an important means for treating hematologic 
malignancies and certain solid tumors.13 Models for CsA-
induced autologous GVHD have been developed in rats 
and mice.14 Several studies have shown that susceptibility 
to autologous GVHD varied greatly from one strain to 
another; DBA/2 and C3H/He but not BALB/c mice are able 
to develop clinical symptoms following autologous stem 
cell transplantation.15 In this study, the shapes of survival 
curves of recipients of allogenetic bone marrow cells suggest 
that CsA or its combination with Fe3O4 MNPs pretreatment 
inhibited aGVHR. The GVHD symptoms and survival in 
the Fe3O4 MNPs group compared with the irradiation-only 
group showed no significant difference, suggesting that low 
concentration of Fe3O4 MNPs has no obvious prevention of 
the incidence of GVHD, though Fe3O4 MNPs could influence 
immune functions of normal imprinting control region mice 
in a dose-dependent manner in the authors’ previous studies.16 
The decreased weight, with other physical characteristics of 
less activity, ruffled fur, and arched back in murine models, 
were improved after allo-HSCT. However, the successful rate 
and long survival time of allogenetic bone marrow transplan-
tation have been limited by transplantation-related mortality. 
GVHD normally develops in clinical settings when allogenetic 
  tissues containing immunocompetent cells are transferred 
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Table 1 Concentration of CsA in different tissues on days 5, 10, 15, 20, and 25 (mean ± sD)
Group Blood,  
μg/L
Tissue, μg/g
Heart Liver Spleen Lung Kidney Brain
CsA 298 ± 17 28 ± 4 600 ± 8 356 ± 5 401 ± 3 122 ± 2 56 ± 3
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to an immunocompromised host.17 The occurrence of this 
frequent scenario in allo-HSCT results from the graft in the 
antigen-specific lymphocytes recognizing the host tissue anti-
gens.18 According to its pathogenesis, a traditional method for 
prevention and treatment of GVHD is to be given high doses 
of immunosuppressive drugs after allo-HSCT.19
Immunotherapy, which may offer a non-cross-resistant 
anticancer mechanism compared with chemotherapy, repre-
sents a potential therapeutic approach for reducing the risk 
of relapse after allo-HSCT.20 CsA, as one of the prevention 
drugs in clinical organ transplantation, can inhibit transplant 
rejection and GVHD and is widely applied and has achieved 
remarkable success. However, the side effects of CsA, include 
neurological damage, gingival hypertrophy, urinary system 
damage, digestive system damage, skin damage, respira-
tory damage, blood system damage, unexplained fever, 
unexplained increase in blood pressure, and other adverse 
reactions.
Based on previous studies,7,8 Fe3O4 MNPs were used as a 
carrier in this present study to increase the concentration of 
CsA tissues and to decelerate the clearance of CsA in murine 
models.18 Subsequent experiments have demonstrated that 
the measured blood parameters in the present study were 
not significantly affected by supporting care of CsA alone 
or in combination with Fe3O4 MNPs, and the irradiated-only 
mice all died of aplastic crisis or infection in 1 week. This 
may be related to the impact of irradiation on the behavioral 
phenotype of the transplanted BALB/c mice with slower 
reconstitution of blood leukocytes.21
Another important finding of this present study is that 
the concentrations of CsA in blood, heart, liver, and spleen 
were all lower in the mice with supporting care of CsA 
than that with coadministration of CsA with Fe3O4 MNPs; 
otherwise, there were no differences in lung, kidney, and brain, 
suggesting that Fe3O4 MNPs can increase the concentration 
of CsA in blood and part tissues, such as heart, liver, and 
spleen. One may argue that the cytostatic effect exerted 
by CsA might be more important in humans than in mice. 
Histopathology with hematoxylin and eosin staining indicated 
that a reduced number of hair follicles and little sebaceous 
glands appended to the hair follicles existed, and a diffuse 
and moderate lymphocytic infiltration was also found around 
hair follicles and extending to the lower surface epidermis 
in the irradiated-only mice, but no noticeable structural 
changes were observed in the mice with supported care 
of CsA, suggesting that Fe3O4 MNPs enhance the CsA on 
the occurrence of a diffuse immune response in the skin of 
recipient mice. Furthermore, focal degeneration and necrosis 
were inconspicuous in both CsA and its combination with 
Fe3O4 MNPs, and fewer inflammatory cells were presented 
in the tissue of  liver when CsA was loaded with Fe3O4 MNPs. 
Similarly, few inflammatory cells and no obvious changes 
were observed in the intestinal tissues of mice after allo-HSCT 
when the supporting care of CsA was loaded with Fe3O4 
MNPs, suggesting that Fe3O4 MNPs are able to enhance the 
effect of CsA on alleviating the liver and intestinal damage 
after allo-HSCT. Fe3O4 MNPs are able to enhance the effect 
of CsA on alleviating the tissue damage in murine models.
Figure 4 Histopathology of skin tissues of mice after allo-HSCT [hematoxylin and eosin, magnification ×4 (objective lens)]. (A) Control group; (B) irradiation-only group; 
(C) Fe3O4 MNPs-treated group; (D) CsA-treated group; (E) CsA + Fe3O4 MNPs-treated group.
Abbreviations: allo-hsCT, allogenetic hematopoietic stem cell transplantation; CsA, cyclosporine A; Fe3O4 MNPs, Fe3O4.magnetic nanoparticles.
Figure 5 Histopathology of liver tissues of mice after allo-HSCT [hematoxylin and eosin, magnification ×4 (objective lens)]. (A) Control group; (B) irradiation-only group; 
(C) Fe3O4 MNPs-treated group; (D) CsA-treated group; (E) CsA + Fe3O4 MNPs-treated group.
Abbreviations: allo-hsCT, allogenetic hematopoietic stem cell transplantation; CsA, cyclosporine A; Fe3O4 MNPs, Fe3O4 magnetic nanoparticles.International Journal of Nanomedicine
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Conclusion
Fe3O4 MNPs may be used as a carrier of an immunosuppressive 
agent to alleviate GVHD after allo-HSCT. Although there is a 
considerable anatomical difference between human bone and 
mouse bone, the basic mechanisms of immunosuppressive 
activity is similar, so further research is needed to clarify the 
most effective CsA dose in combination with Fe3O4 MNPs 
to achieve maximal effects on GVHR.
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Figure 6 Histopathology of intestine tissues of mice after allo-HSCT [hematoxylin and eosin, magnification ×4 (objective lens)]. (A) Control group; (B) irradiation-only 
group; (C) Fe3O4 MNPs-treated group; (D) CsA-treated group; (E) CsA + Fe3O4 MNPs-treated group.
Abbreviations: allo-hsCT, allogenetic hematopoietic stem cell transplantation; CsA, cyclosporine A; Fe3O4 MNPs, Fe3O4 magnetic nanoparticles.